This adverse effect has been recently attributed to the upregulation of AKR1C3 protein, which promotes LD shaping and accumulation, insofar as the selective AKR1C3 inhibition improved Sorafenib resistance in HCC cell lines (45). This evidence concerns the gene AKR1C3 and hepatocellular carcinoma.